5 recruiting, 5 terminated, 2 active not recruiting, 2 completed. 14 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Recruiting 5, Terminated 5, Active not recruiting 2, Completed 2 |
| Phase 1 | 8 | Terminated 3, Completed 2, Recruiting 2, Active not recruiting 1 |
Follow tagraxofusp: new trials by email Literature Review of tagraxofusp trials Research Report on tagraxofusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Tagraxofusp, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Stemline Therapeutics, Inc. | 85 | 2025-01-14 | 2026-08-06 |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents Tagraxofusp, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Joshua Zeidner | 53 | 2024-05-01 | 2026-07-10 |
| Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes Decitabine, Tagraxofusp-erzs - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 64 | 2022-03-04 | 2026-07-14 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia tagraxofusp - Acute Myeloid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 25 | 2021-02-16 | 2025-01-30 |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Cyclophosphamide, Cytarabine, Dexamethasone - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-05-29 | 2026-09-14 |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant Tagraxofusp-erzs - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2020-03-27 | 2024-07-31 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Tagraxofusp Injection - Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Completed | Stemline Therapeutics, Inc. | 82 | 2016-02-10 | 2025-01-06 |
| SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma SL-401 7 µg/kg/day, SL-401 9 µg/kg/day - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Stemline Therapeutics, Inc. | 9 | 2016-01-01 | 2024-04-17 |
| SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Stemline Therapeutics, Inc. | 16 | 2015-02-01 | 2024-10-17 |
| Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Completed | Stemline Therapeutics, Inc. | 138 | 2014-09-01 | 2024-08-01 |
Leukemia, Myeloid, Acute (7) · Blastic Plasmacytoid Dendritic Cell Neoplasm (4) · Leukemia, Myelomonocytic, Chronic (2) · Recurrence (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Multiple Myeloma (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasm, Residual (1) · Pathologic Complete Response (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Stemline Therapeutics, Inc. (5) · M.D. Anderson Cancer Center (4) · French Innovative Leukemia Organisation (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Jacqueline Garcia, MD (1) · Joshua Zeidner (1) · Stanford University (1)
United States (12) · Australia (1) · Canada (1) · France (1) · Italy (1)
Guillermo M Bravo, MD (1) · Jacqueline Garcia, MD (1) · Joshua Zeidner, MD (1) · Naveen Pemmaraju (1) · Nicholas Short, MD (1) · Qaiser Bashir, MS (1)
PMID 31018069, PMID 33795208, PMID 35820082, PMID 40919483, PMID 41146971, PMID 41486505
P30CA016672 (1)